x Acta Scientific | International Open Library | Open Access Journals Publishing Group

Acta Scientific Pharmaceutical Sciences (ASPS)(ISSN: 2581-5423)

Review Article Volume 4 Issue 8

Early Diagnosis, Prophylaxis, Pathophysiology and Current Research On COVID-19

Naresh Daithankar and Shailee Tiwari*

Department of Pharmaceutical Chemistry, Durgamata Institute of Pharmacy, Dharmapuri, Parbhani, India

*Corresponding Author: Shailee Tiwari, Department of Pharmaceutical Chemistry, Durgamata Institute of Pharmacy, Dharmapuri, Parbhani, India.

Received: July 01, 2020; Published: July 28, 2020

Reprints View PDF Related Articles

×

Abstract

 In December 2019, the outbreak of the novel coronavirus disease (COVID-19) in China spread worldwide, becoming an emergency of major international concern. The SARS-CoV-2 infection causes a severe respiratory illness similar to severe acute respiratory syndrome coronavirus. Human-to-human transmission via droplets, contaminated hands or surfaces has been described, with incubation times of 2-14 days. This paper reviews the literature on all available information about the diagnosis, prophylaxis, pathophysiology and Current research on COVID-19. Current research on COVID-19 including antimalarial drugs (chloroquine and hydroxychloroquine), antiviral drugs (Ribavirin, remdesivir), antibodies, vaccines and convalescent plasma transfusion, are discussed in this article.

Keywords: COVID-19; Pandemic; Diagnosis; Prophylaxis; Current Research; Remdesivir

×

References

  1. Zhu N., et al. “A novel coronavirus from patients with pneumonia in China, 2019”. The New England Journal of Medicine 382 (2020): 727–330.
  2. Lu R., et al. “Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding”. Lancet 395 (2020): 565–574.
  3. Bhadra., et al. “Real-time sequence-validated loop-mediated isothermal amplification assays for detection of Middle East respiratory syndrome coronavirus (MERS-CoV)”. PLoS One 10 (2015): e0123126.
  4. JF Chan., et al. “Development and evaluation of novel real-time reverse transcription-PCR Assays with locked nucleic acid probes targeting leader sequences of human-pathogenic Coronaviruses”. Journal of Clinical Microbiology (2015).
  5. P Huang., et al. “A Rapid and Specific Assay for the Detection of MERS-CoV”. Frontiers in Microbiology (2018).
  6. SH Lee., et al. “One-pot reverse transcriptional loop-mediated isothermal amplification (RT-LAMP) for detecting MERS-CoV”. Frontiers in Microbiology 7 (2017): 2166.
  7. DKW Chu., et al. “Molecular diagnosis of a novel Coronavirus (2019-nCoV) causing an outbreak of pneumonia”. Clinical Chemistry4 (2020): 549–555.
  8. JF Chan., et al. “Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-polymerase chain reaction assay validated in vitro and with clinical specimens”.
  9. R Konrad., et al. “Rapid establishment of laboratory diagnostics for the novel coronavirus SARS-CoV-2 in Bavaria, Germany, February 2020”. Europe's Journal on Infectious Disease Surveillance, Epidemiology, Prevention and Control 9 (2020).
  10. X Xie., et al. “Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing”. Radiology (2020).
  11. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457962/
  12. https://en.wikipedia.org/wiki/Novel_coronavirus_ (2019-nCoV)
  13. https://en.wikipedia.org/wiki/Coronavirus
  14. A Savarino., et al. “New insights into the antiviral effects of chloroquine”. Lancet Infection Disease2 (2006): 67–69.
  15. Y Yan., et al. “Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model”. Cell Research32 (2013): 300–302.
  16. JM Rolain., et al. “Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century”. International Journal of Antimicrobial Agents4 (2007): 297-308.
  17. MJ Vincent., et al. “Chloroquine is a potent inhibitor of SARS coronavirus infection and spread”. Virology Journal (2005).
  18. J Gao., et al. “Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies”. Bioscience Trends1 (2020): 72-73.
  19. “Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia”.
  20. M Jallouli., et al. “Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus”. Arthritis Rheumatology8 (2015): 2176-2184.
  21. C Biot., et al. “Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities”. 9 (2006): 2845–2849.
  22. E Schrezenmeier and T Dorner. “Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology”. Nature Reviews Rheumatology 16 (2020): 155–166.
  23. A Savarino., et al. “Effects of chloroquine on viral infections: an old drug against today's diseases”. The Lancet11 (2003): P722-727.
  24. F Touret X. “de Lamballerie of chloroquine and COVID-19”.
  25. P Colson., et al. “Chloroquine for the 2019 novel coronavirus SARS-CoV-2”.
  26. TT Yao., et al. “A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option”. Journal of Medicine Virology (2020).
  27. S Mulangu., et al. “A randomized, controlled trial of Ebola virus disease therapeutics”. (2019).
  28. EP Tchesnokov., et al. “Mechanism of inhibition of Ebola virus RNA-dependent RNA Polymerase by remdesivir”.
  29. TP Sheahan., et al. “Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV”. Nature Communications 11 (2020).
  30. ML Holshue., et al. “First case of 2019 novel Coronavirus in the United States”.
  31. article/explained/two-antibodies-from-sars-survivors-and-how-they-react-to-new-coronavirus-6419947
  32. S Mulangu., et al. “A randomized, controlled trial of Ebola virus disease therapeutics”.
  33. D Wrapp., et al. “Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation”. Science 6483 (2020): 1260-1263.
  34. XW Xu., et al. “Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series”. BMJ 368 (2020): m606.
×

Citation

Citation: Naresh Daithankar and Shailee Tiwari. “Early Diagnosis, Prophylaxis, Pathophysiology and Current Research On COVID-19". Acta Scientific Pharmaceutical Sciences 4.8 (2020): 107-111.




Metrics

Acceptance rate32%
Acceptance to publication20-30 days
Impact Factor0.759

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is April 25, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

    • Contact US





    +91 9182824667

         info@acta-scientific.com

    Creative Commons License Open Access by Acta Scientific is licensed under a Creative Commons Attribution 4.0 International License
    Based on a work at https://actascientific.com

    ff

    Acta-Publications

    ff

    © 2021 Acta Scientific, All rights reserved.